Statements (62)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:fragrance
|
| gptkbp:activities |
factor Xa inhibitor
|
| gptkbp:appointed_by |
oral tablet
|
| gptkbp:approves |
gptkb:legislation
gptkb:2015 gptkb:FDA gptkb:United_States |
| gptkbp:brand |
Savaysa
|
| gptkbp:clinical_trial |
Phase III
|
| gptkbp:contraindication |
pregnancy
active bleeding severe renal impairment lactation |
| gptkbp:counseling_services |
report any unusual bleeding
take at the same time each day do not stop taking without consulting a doctor avoid activities that may increase risk of bleeding inform healthcare provider of all medications taken |
| gptkbp:developed_by |
gptkb:Daiichi_Sankyo
|
| gptkbp:discovered_by |
gptkb:Daiichi_Sankyo
|
| gptkbp:dosage_form |
gptkb:tablet
oral tablet 15 mg 30 mg 60 mg |
| gptkbp:excretion |
urine
|
| https://www.w3.org/2000/01/rdf-schema#label |
Edoxaban
|
| gptkbp:indication |
venous thromboembolism
non-valvular atrial fibrillation |
| gptkbp:ingredients |
C21 H25 N3 O5 S
|
| gptkbp:interacts_with |
antiplatelet agents
other anticoagulants NSAI Ds |
| gptkbp:is_available_on |
generic version
|
| gptkbp:is_monitored_by |
renal function
liver function |
| gptkbp:is_used_for |
treatment of deep vein thrombosis
treatment of pulmonary embolism preventing stroke treating deep vein thrombosis treating pulmonary embolism prevention of stroke |
| gptkbp:lifespan |
10 to 14 hours
9 to 11 hours |
| gptkbp:manager |
oral
|
| gptkbp:marketed_as |
gptkb:legislation
gptkb:Japan gptkb:United_States |
| gptkbp:metabolism |
liver
hepatic |
| gptkbp:side_effect |
gptkb:fandom
gastrointestinal bleeding bleeding liver enzyme elevation skin rash thrombocytopenia |
| gptkbp:suitable_for |
severe hepatic impairment
active peptic ulcer disease history of intracranial hemorrhage recent major surgery |
| gptkbp:traded_on |
Lixiana
|
| gptkbp:weight |
429.56 g/mol
|